Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Watch
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Career Center|
Radiation Oncology|
Surgery
Advertisement

Kathryn Arbour, MD

Advertisement

Articles by Kathryn Arbour, MD

Kathryn Arbour, MD, on the Development of KRAS G12C Inhibitors in Lung Cancer

ByKathryn Arbour, MD
November 19th 2019

The MSK expert discusses exciting advancements in the field of immunotherapy for treating lung cancer at the Annual New York Lung Cancers Symposium®.

Advertisement

Latest Updated Articles

  • Kathryn Arbour, MD, on the Development of KRAS G12C Inhibitors in Lung Cancer
    Kathryn Arbour, MD, on the Development of KRAS G12C Inhibitors in Lung Cancer

    November 19th 2019



Advertisement
Advertisement

Trending on CancerNetwork

1

What Separates a Next-Generation Liver Tumor Board From the Traditional Model?

2

Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant

3

BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC

4

MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance

5

Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us